Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
By D. Borger, Kenneth K. Tanabe, Kenneth C. Fan, H. Lopez, Valeria R. Fantin, K. Straley, David P. Schenkein, A. Hezel, M. Ancukiewicz, Hannah M. Liebman and 8 more. The Oncologist, 2012
743 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/2743d832e4e7b311cf3645c63dad08abc4aa6f2b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Surgery
Citations in the corpus
- Cholangiocarcinoma — evolving concepts and therapeutic strategies (2017, neutral): “Consistent with prior reports 92,95,103,104 , mutations in IDH1 or IDH2 were detected exclusively in iCCA, and were highly enriched in a novel, distinct molecular iCCA subtype identified through clusterofcluster analysis of gene expression, DNAmethylation, and copynumber profiles 101 .”
- Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017, neutral): “, 2016), and had high risk scores based on a gene expression signature of 65 genes (Borger et al., 2012) (Figure 4A), suggesting that HCC with the IDH-like gene expression signature represents a poor prognostic subtype of HCC.”
- Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma (2013, methodology): “A subsequent analysis of 62 CCAs detected IDH1mutations in only iCCAs.(75) IDH1 and IDH2 mutations were associated significantly with increased levels of p53 and DNA hypermethylation.”
- The Definition of Primary and Secondary Glioblastoma (2012, background): “Exceptions are central chondrosarcomas (~55%) (16), intrahepatic cholangio-carcinomas (23%) (17), acute myeloid leukemia (AML; 15–20%) (18-23), angioimmunoblastic T-cell lymphoma (AITL; ~20%) (24) malignant melanoma (~10%) (25), and anaplastic thyroid cancer (~10%) (26).”